SCHEMBL15869553

SCHEMBL15869553

CS(=O)(=O)c1ccc(C(=O)NN2C(=O)/C(=C/c3ccc(Oc4ccccc4)cc3)SC2=S)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 15/20 0.67
▸ MEN1 O00255 14/20 0.67
▸ POLB P06746 3/20 0.67
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ ALPL P05186 1/20 0.58
▸ PKM P14618 1/20 0.55
▸ MAPT P10636 6/20 0.53
▸ PTPN1 P18031 2/20 0.53
▸ MMP3 P08254 1/20 0.53
▸ AKR1B1 P15121 1/20 0.53
▸ MMP13 P45452 1/20 0.53
▸ LMNA P02545 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ OPRK1 P41145 1/20 0.53
▸ ALDH1A1 P00352 1/20 0.51
▸ HPGD P15428 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ NPY2R P49146 1/20 0.51
▸ HTT P42858 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15863656 1.00 KMT2A (0.67) KMT2AMEN1POLBL3MBTL1ALPL
SCHEMBL15863655 1.00 KMT2A (0.67) KMT2AMEN1POLBL3MBTL1ALPL
SCHEMBL18103048 0.76 KMT2A (0.64) KMT2AMEN1POLBL3MBTL1ALPL
SCHEMBL31707337 0.75 MAPT (0.77) KMT2AMEN1POLBL3MBTL1ALPL
SCHEMBL18102995 0.72 KMT2A (0.70) KMT2AMEN1POLBL3MBTL1ALPL
SCHEMBL15347346 0.71 KMT2A (0.78) KMT2AMEN1POLBL3MBTL1PKM
SCHEMBL15359666 0.71 KMT2A (0.78) KMT2AMEN1POLBL3MBTL1PKM
SCHEMBL15347344 0.71 KMT2A (0.78) KMT2AMEN1POLBL3MBTL1PKM
SCHEMBL6779900 0.71 KMT2A (1.00) KMT2AMEN1POLBL3MBTL1MAPT
SCHEMBL6779898 0.71 KMT2A (1.00) KMT2AMEN1POLBL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9056862-B2 Thioxothiazolidine derivative having Ras function inhibitory effect NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2015-06-16 — — US disclosed
US-9056862-B2 Thioxothiazolidine derivative having Ras function inhibitory effect NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2015-06-16 — — US disclosed
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KNC LABORATORIES CO., LTD. (JP) 2014-07-10 — — US disclosed
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KNC LABORATORIES CO., LTD. (JP) 2014-07-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140194412-A1 THIOXOTHIAZOLIDINE DERIVATIVE HAVING RAS FUNCTION INHIBITORY EFFECT KRAS, NRAS, RASSF5 KMT2A 1805/4885MEN1 762/4885POLB 4545/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback